Biotech | November 26, 2024
FDA approves BridgeBio’s Attruby for ATTR-CM treatment
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
CSPC will receive an upfront payment of $100 million from AstraZeneca
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Subscribe To Our Newsletter & Stay Updated
